These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs. Lester A; Sandman M; Herring C; Girard C; Dixon B; Ramsdell H; Reber C; Poulos J; Mitchell A; Spinney A; Henager ME; Evans CN; Turlington M; Johnson QR Biochemistry; 2023 Aug; 62(16):2503-2515. PubMed ID: 37437308 [TBL] [Abstract][Full Text] [Related]
4. Lumacaftor and Matrine: Possible Therapeutic Combination to Counteract the Inflammatory Process in Cystic Fibrosis. Pecoraro M; Franceschelli S; Pascale M Biomolecules; 2021 Mar; 11(3):. PubMed ID: 33805605 [TBL] [Abstract][Full Text] [Related]
5. Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics. Kim M; McDonald EF; Sabusap CMP; Timalsina B; Joshi D; Hong JS; Rab A; Sorscher EJ; Plate L J Biol Chem; 2023 Oct; 299(10):105242. PubMed ID: 37690692 [TBL] [Abstract][Full Text] [Related]
6. General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants. McKee AG; McDonald EF; Penn WD; Kuntz CP; Noguera K; Chamness LM; Roushar FJ; Meiler J; Oliver KE; Plate L; Schlebach JP Cell Chem Biol; 2023 Jun; 30(6):632-642.e5. PubMed ID: 37253358 [TBL] [Abstract][Full Text] [Related]
7. CFTR Folding: From Structure and Proteostasis to Cystic Fibrosis Personalized Medicine. McDonald EF; Meiler J; Plate L ACS Chem Biol; 2023 Oct; 18(10):2128-2143. PubMed ID: 37730207 [TBL] [Abstract][Full Text] [Related]
8. Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing. Fossa P; Uggeri M; Orro A; Urbinati C; Rondina A; Milanesi M; Pedemonte N; Pesce E; Padoan R; Ford RC; Meng X; Rusnati M; D'Ursi P Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293130 [TBL] [Abstract][Full Text] [Related]
10. The CFTR Corrector, VX-809 (Lumacaftor), Rescues ABCA4 Trafficking Mutants: a Potential Treatment for Stargardt Disease. Liu Q; Sabirzhanova I; Bergbower EAS; Yanda M; Guggino WG; Cebotaru L Cell Physiol Biochem; 2019; 53(2):400-412. PubMed ID: 31403270 [TBL] [Abstract][Full Text] [Related]
11. Combination of Correctors Rescues CFTR Transmembrane-Domain Mutants by Mitigating their Interactions with Proteostasis. Lopes-Pacheco M; Boinot C; Sabirzhanova I; Rapino D; Cebotaru L Cell Physiol Biochem; 2017; 41(6):2194-2210. PubMed ID: 28448979 [TBL] [Abstract][Full Text] [Related]
12. ABC-transporter CFTR folds with high fidelity through a modular, stepwise pathway. Im J; Hillenaar T; Yeoh HY; Sahasrabudhe P; Mijnders M; van Willigen M; Hagos A; de Mattos E; van der Sluijs P; Braakman I Cell Mol Life Sci; 2023 Jan; 80(1):33. PubMed ID: 36609925 [TBL] [Abstract][Full Text] [Related]
14. ΔF508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles. Ye L; Hu B; El-Badri F; Hudson BM; Phuan PW; Verkman AS; Tantillo DJ; Kurth MJ Bioorg Med Chem Lett; 2014 Dec; 24(24):5840-5844. PubMed ID: 25452003 [TBL] [Abstract][Full Text] [Related]
15. Redefining Hypo- and Hyper-Responding Phenotypes of CFTR Mutants for Understanding and Therapy. Hillenaar T; Beekman J; van der Sluijs P; Braakman I Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499495 [TBL] [Abstract][Full Text] [Related]
16. Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics. Kim M; McDonald EF; Sabusap CMP; Timalsina B; Joshi D; Hong JS; Rab A; Sorscher EJ; Plate L bioRxiv; 2023 Feb; ():. PubMed ID: 36778339 [TBL] [Abstract][Full Text] [Related]
18. On the design of broad based screening assays to identify potential pharmacological chaperones of protein misfolding diseases. Naik S; Zhang N; Gao P; Fisher MT Curr Top Med Chem; 2012; 12(22):2504-22. PubMed ID: 23339304 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and Evaluation of Bithiazole Derivatives As Potential α-Sarcoglycan Correctors. Ribaudo G; Carotti M; Ongaro A; Oselladore E; Scano M; Zagotto G; Sandonà D; Gianoncelli A ACS Med Chem Lett; 2023 Aug; 14(8):1049-1053. PubMed ID: 37583821 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and photochemical properties of the first examples of iminosugar clusters based on fluorescent cores. Lepage ML; Mirloup A; Ripoll M; Stauffert F; Bodlenner A; Ziessel R; Compain P Beilstein J Org Chem; 2015; 11():659-67. PubMed ID: 26124868 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]